‘[The trials] began early last week. The first group of volunteers underwent health screenings last Thursday, was hospitalized on Sunday and received a dose of the vaccine on October 28. We plan to engage 110 people into the research ,” he said in an interview with Russia’s Izvestia newspaper.
The first group of volunteers comprises 28 members, including people with chronic conditions typical for the elderly, such as diabetes, hypertension and chronic renal insufficiency. The oldest person in the group is 82 years of age.
“ We noticed no [negative] reactions, at least in the first group of patients: no skin reactions, no increased body temperature, no preclinical [flu] symptoms ,” the researcher went on.
According to Lomakin, the majority of volunteers aged below 60 years complained of malaise and increased body temperature within the first 24-49 hours after receiving the vaccine. However, no such reactions were observed in the elderly group.
The researcher attributed the trend to the fact that human immune system becomes more suppressed with age, TASS reported.
The second group of about 25-40 elderly volunteers is expected to be convoked on November 1 the third one – a week later. All volunteers have been insured.
Unlike the post-registration trials on 40000 volunteers also under way at the moment, the study involving elderly persons is not placebo-controlled.
“ Preliminary conclusions [about the outcome of the trials] can be made on the 42nd day ,” the Russian doctor said.
On August 11 the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by Russia’s Health Ministry and became the world’s first registered vaccine against COVID-19. Post-registration trials began in Moscow on September 7. First doses of the vaccine were administered on September 9. Overall, the trial program involves some 40000 people, including 10000 people who received placebo instead of the vaccine.
The Russian Health Ministry’s press service announced earlier this week that it had issued a permission to carry out separate clinical trials of the vaccine on volunteers aged 60 and older.
Earlier on October 27 Russia announced that EpiVacCorona,
second vaccine
in this country to fight the Covid-19 pandemic, started production, the national epidemiological surveillance entity Rospatrebnadzor informed, Plengish reported.
Rospatrebnadzor head Anna Popova stated that the serial production of the aforementioned vaccine started at Russia’s ‘Vektor’ State Research Center for Virology and Biotechnologies. The record of which was informed on October 14 by President Vladimir Putin.
The vaccine is based on synthetic materials, so its third phase or post-registration tests will be conducted in people aged 65 years, unlike the first one, Sputnik V, whose registration on August 11 was the first of its kind globally.
Russia is also developing a third vaccine at the ‘M.P.Chumakov’ Federal Scientific Center for Research and Development of Immunobiological Preparations, in Saint Petersburg, to fight the aforementioned pandemic.
The global race to find the Covid-19 vaccines has never been this firece, with giant pharmeutical companies around the world are doing their utmost to roll out vaccine in the quickest time. Russia, the US, UK and China are in the forefront.
To date, the world has reported over 46.8 million cases, and over 1.2 million deaths. The US, India and Brazil are still the three hardest-hit countries by the pandemic.
